TPTX » Topics » (3) Net Loss Per Share

This excerpt taken from the TPTX DEF 14A filed Jun 19, 2009.

(5) Net Loss Per Share

We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share. Net loss per share is computed on the basis of the weighted-average number of shares of common stock outstanding during the periods presented. Net loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents. For the three-month periods ended March 31, 2009 and 2008, there is no difference between basic and diluted net loss per share attributable to common stockholders because the effect of common stock equivalents outstanding during the periods, including stock options, restricted stock units and warrants, is antidilutive.

This excerpt taken from the TPTX 10-Q filed May 1, 2009.

(5) Net Loss Per Share

We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share. Net loss per share is computed on the basis of the weighted-average number of shares of common stock outstanding during the periods presented. Net loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents. For the three-month periods ended March 31, 2009 and 2008, there is no difference between basic and diluted net loss per share attributable to common stockholders because the effect of common stock equivalents outstanding during the periods, including stock options, restricted stock units and warrants, is antidilutive.

This excerpt taken from the TPTX 10-K filed Mar 27, 2009.

Net Loss per Share

We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share. Net loss per share is computed on the basis of the weighted-average number of common shares outstanding during the periods presented. Loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents. Net loss per share attributable to common stockholders assuming dilution for the years ended December 31, 2008, 2007 and 2006 is equal to net loss per share attributable to common stockholders since the effect of common stock equivalents outstanding during the periods, including stock options, restricted stock units and warrants, is antidilutive.

 

F-10


Table of Contents

Shares used in calculating basic and diluted net loss per common share exclude these potential common shares (in thousands):

 

     Years Ended December 31,
         2008            2007            2006    

Antidilutive options to purchase common stock

   2,073    1,606    1,408

Antidilutive warrants to purchase common stock

   2,148    2,410    2,464

Antidilutive restricted stock units

   105    195    155
              
   4,326    4,211    4,027
              
This excerpt taken from the TPTX 10-Q filed Nov 12, 2008.

(4) Net Loss Per Share

We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share. Net loss per share is computed on the basis of the weighted-average number of shares of common stock outstanding during the periods presented. Net loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents. For the three and nine months ended September 30, 2008 and 2007, there is no difference between basic and diluted net loss per share attributable to common stockholders because the effect of common stock equivalents outstanding during the periods, including stock options, restricted stock units and warrants, is antidilutive.

This excerpt taken from the TPTX 10-Q filed Aug 12, 2008.

(4) Net Loss Per Share

We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share. Net loss per share is computed on the basis of the weighted-average number of shares of common stock outstanding during the periods presented. Net loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents. For the three and six months ended June 30, 2008 and 2007, there is no difference between basic and diluted net loss per share attributable to common stockholders because the effect of common stock equivalents outstanding during the periods, including stock options, restricted stock units and warrants, is antidilutive.

This excerpt taken from the TPTX 10-Q filed May 13, 2008.

(4) Net Loss Per Share

 

We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share.  Net loss per share is computed on the basis of the weighted-average number of shares of common stock outstanding during the periods presented.  Net loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents.  For the three-month periods ended March 31, 2008 and 2007, there is no difference between basic and diluted net loss per share attributable to common stockholders because the effect of common stock equivalents outstanding during the periods, including stock options, restricted stock units and warrants, is antidilutive.

 

These excerpts taken from the TPTX 10-K filed Mar 31, 2008.

Net Loss per Share

        We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share. Net loss per share is computed on the basis of the weighted-average number of common shares outstanding during the periods presented. Loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents. Net loss per share attributable to common stockholders assuming dilution for the years ended December 31, 2007, 2006 and 2005 is equal to net loss per share attributable to common stockholders since the effect of common stock equivalents outstanding during the periods, including stock options, restricted stock units, warrants and redeemable convertible preferred stock, is antidilutive.

        Shares used in calculating basic and diluted net loss per common share exclude these potential common shares (in thousands):

 
  Years Ended December 31,
 
  2007
  2006
  2005
Antidilutive options to purchase common stock   1,606   1,408   856
Antidilutive warrants to purchase common stock   2,410   2,464   199
Antidilutive restricted stock units   195   155  
Antidilutive redeemable convertible preferred stock (as-if converted to common stock)       7,268
   
 
 
    4,211   4,027   8,323
   
 
 

F-10


TorreyPines Therapeutics, Inc.

Notes to Consolidated Financial Statements (Continued)

December 31, 2007

1. Organization and Summary of Significant Accounting Policies (Continued)

Net Loss per Share



        We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share. Net loss per share is
computed on the basis of the weighted-average number of common shares outstanding during the periods presented. Loss per share assuming dilution is computed on the basis of the weighted-average number
of common shares outstanding and the dilutive effect of all common stock equivalents. Net loss per share attributable to common stockholders assuming dilution for the years ended December 31,
2007, 2006 and 2005 is equal to net loss per share attributable to common stockholders since the effect of common stock equivalents outstanding during the periods, including stock options, restricted
stock units, warrants and redeemable convertible preferred stock, is antidilutive.



        Shares
used in calculating basic and diluted net loss per common share exclude these potential common shares (in thousands):


















































































 
 Years Ended December 31,
 
 2007
 2006
 2005
Antidilutive options to purchase common stock 1,606 1,408 856
Antidilutive warrants to purchase common stock 2,410 2,464 199
Antidilutive restricted stock units 195 155 
Antidilutive redeemable convertible preferred stock (as-if converted to common stock)   7,268
  
 
 
  4,211 4,027 8,323
  
 
 



F-10








TorreyPines Therapeutics, Inc.



Notes to Consolidated Financial Statements (Continued)



December 31, 2007



1. Organization and Summary of Significant Accounting Policies (Continued)



This excerpt taken from the TPTX 10-Q filed Nov 14, 2007.

(3) Net Loss Per Share

We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share.  Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the periods presented.  Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding increased to include potentially dilutive common stock equivalents outstanding during the period.  For the three- and nine-month periods ended September 30, 2007 and 2006, there is no difference between basic and diluted net loss per share attributable to common stockholders because the effect of common stock equivalents outstanding during the periods, including stock options, restricted stock units, warrants and redeemable convertible preferred stock, is antidilutive.

This excerpt taken from the TPTX 10-Q filed Aug 14, 2007.

(3) Net Loss Per Share

We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share.  Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the periods presented.  Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding increased to include potentially dilutive common stock equivalents outstanding during the period.  For the three- and six-month periods ended June 30, 2007 and 2006, there is no difference between basic and diluted net loss per share attributable to common stockholders because the effect of common stock equivalents outstanding during the periods, including stock options, restricted stock units, warrants and redeemable convertible preferred stock, is antidilutive.

This excerpt taken from the TPTX 10-Q filed May 14, 2007.

(3) Net Loss Per Share

We calculate net loss per share in accordance with SFAS No. 128, Earnings Per Share.  Net loss per share is computed on the basis of the weighted-average number of shares of common stock outstanding during the periods presented.  Net loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents.  For the three-month periods ended March 31, 2007 and 2006, there is no difference between basic and diluted net loss per share attributable to common stockholders because the effect of common stock equivalents outstanding during the periods, including stock options, warrants and redeemable convertible preferred stock, is antidilutive.

4




This excerpt taken from the TPTX 10-K filed Mar 29, 2007.

Net Loss per Share

The Company calculates net loss per share in accordance with SFAS No. 128, Earnings Per Share. Net loss per share is computed on the basis of the weighted-average number of common shares outstanding during the periods presented. Loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents. Net loss per share attributable to common stockholders assuming dilution for the years ended December 31, 2006, 2005 and 2004 is equal to net loss per share attributable to common stockholders since the effect of common stock equivalents outstanding during the periods, including stock options, warrants and redeemable convertible preferred stock, is antidilutive.

F-10




TorreyPines Therapeutics, Inc.
Notes to Consolidated Financial Statements (Continued)
December 31, 2006

These excerpts taken from the TPTX 8-K filed Dec 13, 2006.

3. Net Loss Per Share

The Company calculates net loss per share in accordance with SFAS No. 128, Earnings Per Share. Net loss per share is computed on the basis of the weighted-average number of shares of common stock outstanding during the periods presented. Loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents. Net loss per share attributable to common stockholders assuming dilution for the three- and nine-month periods ended September 30, 2006 and 2005 is equal to net loss per share attributable to common stockholders since the effect of common stock equivalents outstanding during the periods, including stock options, warrants and redeemable convertible preferred stock, is antidilutive.

Net Loss per Share

The Company calculates net loss per share in accordance with SFAS No. 128,Earnings Per Share. Net loss per share is computed on the basis of the weighted-average number of common shares outstanding during the periods presented. Loss per share assuming dilution is computed on the basis of the weighted-average number of common shares outstanding and the dilutive effect of all common stock equivalents. Net loss per share attributable to common stockholders assuming dilution for the years ended December 31, 2003, 2004 and 2005 is equal to net loss per share attributable to common stockholders since the effect of common stock equivalents outstanding during the periods, including stock options, warrants and redeemable convertible preferred stock, is antidilutive.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki